Choreo LLC Sells 1,935 Shares of Eli Lilly and Company (NYSE:LLY)

Choreo LLC lowered its holdings in Eli Lilly and Company (NYSE:LLY) by 6.3% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 28,551 shares of the company’s stock after selling 1,935 shares during the period. Choreo LLC’s holdings in Eli Lilly and Company were worth $22,078,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Tectonic Advisors LLC lifted its holdings in shares of Eli Lilly and Company by 16.4% during the 4th quarter. Tectonic Advisors LLC now owns 3,890 shares of the company’s stock worth $3,003,000 after acquiring an additional 548 shares during the period. Confluence Wealth Services Inc. lifted its holdings in shares of Eli Lilly and Company by 23.4% during the 4th quarter. Confluence Wealth Services Inc. now owns 8,794 shares of the company’s stock worth $6,741,000 after acquiring an additional 1,665 shares during the period. Country Club Bank lifted its holdings in shares of Eli Lilly and Company by 27.1% during the 4th quarter. Country Club Bank now owns 3,378 shares of the company’s stock worth $2,614,000 after acquiring an additional 720 shares during the period. Berkshire Money Management Inc. bought a new stake in shares of Eli Lilly and Company during the 4th quarter worth approximately $302,000. Finally, Lockheed Martin Investment Management Co. lifted its holdings in shares of Eli Lilly and Company by 38.8% during the 4th quarter. Lockheed Martin Investment Management Co. now owns 23,290 shares of the company’s stock worth $17,980,000 after acquiring an additional 6,510 shares during the period. Institutional investors own 82.53% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the stock. Sanford C. Bernstein assumed coverage on shares of Eli Lilly and Company in a report on Thursday, October 17th. They set an “outperform” rating and a $1,100.00 price target for the company. Redburn Atlantic raised shares of Eli Lilly and Company to a “hold” rating in a report on Monday, November 4th. Truist Financial upped their price objective on shares of Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the stock a “buy” rating in a research report on Monday. StockNews.com cut shares of Eli Lilly and Company from a “buy” rating to a “hold” rating in a research report on Thursday, January 30th. Finally, Citigroup lowered their price objective on shares of Eli Lilly and Company from $1,250.00 to $1,190.00 and set a “buy” rating for the company in a research report on Tuesday, January 28th. Five research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. According to data from MarketBeat, Eli Lilly and Company has a consensus rating of “Moderate Buy” and a consensus price target of $997.50.

Eli Lilly and Company Trading Up 3.4 %

Shares of NYSE LLY opened at $870.56 on Friday. Eli Lilly and Company has a 52-week low of $707.02 and a 52-week high of $972.53. The company has a debt-to-equity ratio of 2.03, a quick ratio of 0.97 and a current ratio of 1.27. The firm has a 50 day moving average price of $786.57 and a two-hundred day moving average price of $843.28. The stock has a market cap of $826.44 billion, a P/E ratio of 94.11, a price-to-earnings-growth ratio of 1.72 and a beta of 0.42.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, February 6th. The company reported $5.32 earnings per share for the quarter, missing the consensus estimate of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 71.08% and a net margin of 20.48%. As a group, equities analysts forecast that Eli Lilly and Company will post 12.85 EPS for the current year.

Eli Lilly and Company declared that its board has authorized a share repurchase plan on Monday, December 9th that allows the company to repurchase $15.00 billion in outstanding shares. This repurchase authorization allows the company to repurchase up to 2% of its shares through open market purchases. Shares repurchase plans are typically a sign that the company’s management believes its shares are undervalued.

Eli Lilly and Company Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, March 10th. Investors of record on Friday, February 14th will be paid a dividend of $1.50 per share. The ex-dividend date is Friday, February 14th. This is a positive change from Eli Lilly and Company’s previous quarterly dividend of $1.30. This represents a $6.00 annualized dividend and a yield of 0.69%. Eli Lilly and Company’s dividend payout ratio is currently 56.22%.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.